A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Not Recruiting

Trial ID: NCT01677390


This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.

Official Title

A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression

   - Previously treated with at least 1 tyrosine kinase inhibitor (TKI)

   - Measurable disease

   - Eastern Cooperative Oncology Group performance status 0 or 1

   - Adequate lung and renal function

Exclusion Criteria:

   - Prior treatment with anti-CD70-directed therapy

   - Received more than one prior treatment with an mTOR inhibitor


drug: SGN-75

drug: everolimus

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.